Market Overview

UPDATE: Credit Suisse Initiates AbbVie at Neutral on Humira Dependence

Share:
Related ABBV
AbbVie Initiates Pivotal Phase 3 Study of Veliparib for Patients with Early-Stage Triple-Negative Breast Cancer
Enanta Pharmaceuticals Announces Additional Data from AbbVie's M13-393 Study to be Presented at Liver Meeting
Google Regroups, Thunders Into Health Tech (Investor's Business Daily)

Credit Suisse initiated AbbVie (NYSE: ABBV) with a Neutral rating and a $37.00 price target.

Credit Suisse noted, "AbbVie's cross-currents imply minimal stock movement from current price. Growth is modest with 2013-2020 sales and EPS CAGR at 2% and 3% respectively and only 20% revenue contribution from the pipeline by 2020. Humira contribution to ABBV is significant; contribution to sales '13-20 is at minimum 50%, and over 70% to profits. Positives: ~9% free cash flow yield, 4.3% dividend yield, 11.9x P/E (pharma 2013 average 13.9x), options on elagolix, ABT-199 for lymphoma & business development (BD). Negatives: overdependence on Humira and long-term competitive threat from orals and biosimilars, HCV franchise expectations already realistic."

AbbVie closed at $75.39 on Wednesday.

Latest Ratings for ABBV

DateFirmActionFromTo
Jul 2015Deutsche BankMaintainsBuy
Jul 2015SunTrust Robinson HumphreyInitiates Coverage onBuy
Jun 2015Piper JaffrayInitiates Coverage onOverweight

View More Analyst Ratings for ABBV
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Initiation Analyst Ratings

 

Related Articles (ABBV)

Get Benzinga's Newsletters